MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study

Mar 15, 2012International journal of radiation oncology, biology, physics

MGMT gene methylation linked to outcomes in glioblastoma patients treated with temozolomide and radiation

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

The median overall survival for patients with methylated MGMT genes was 29 months compared to 20 months for those with unmethylated genes.

MGMT gene methylation is associated with significantly better overall survival and progression-free survival in glioblastoma multiforme patients.
In a cohort of 93 patients, those with methylated MGMT genes had a median overall survival of 29 months.
The 2-year overall survival rate for patients with methylated MGMT was 54%, while the 5-year rate was 31%.
Combined factors of methylated MGMT genes, age ≤50 years, and total or subtotal resections were linked to extended survival, with some patients alive 38 to 77 months post-operation.
Patients with unmethylated MGMT genes, age over 50, and less than subtotal resections had a median overall survival of 13.2 months.

AI simplified

PURPOSE: Recently, cells deficient in O(6)-methylguanine-DNA methyltransferase (MGMT) were found to show increased sensitivity to temozolomide (TMZ). We evaluated whether hypermethylation of MGMT was associated with survival in patients with glioblastoma multiforme (GBM).

METHODS AND MATERIALS: We retrospectively analyzed 93 patients with histologically confirmed GBM who received involved-field radiotherapy with TMZ from 2001 to 2008. The median age was 58 years (range, 24-78 years). Surgical resection was total in 39 patients (42%), subtotal in 30 patients (32%), and partial in 17 patients (18%); only a biopsy was performed in 7 patients (8%). Postoperative radiotherapy began within 3 weeks of surgery in 87% of the patients. Radiotherapy doses ranged from 50 to 74 Gy (median, 70 Gy). MGMT gene methylation was determined in 78 patients; MGMT was unmethylated in 43 patients (55%) and methylated in 35 patients (45%). The median follow-up period was 22 months (range, 3-88 months) for all patients.

RESULTS: The median overall survival (OS) was 22 months, and progression-free survival (PFS) was 11 months. MGMT gene methylation was an independently significant prognostic factor for both OS (p = 0.002) and PFS (p = 0.008) in multivariate analysis. The median OS was 29 months for the methylated group and 20 months for the unmethylated group. In 35 patients with methylated MGMT genes, the 2-year and 5-year OS rates were 54% and 31%, respectively. Six patients with combined prognostic factors of methylated MGMT genes, age ≤50 years, and total/subtotal resections are all alive 38 to 77 months after operation, whereas the median OS in 8 patients with unmethylated MGMT genes, age >50 years, and less than subtotal resection was 13.2 months.

CONCLUSION: We confirmed that MGMT gene methylation is a potent prognostic factor in patients with GBM. Our results suggest that early postoperative radiotherapy and a high total/subtotal resection rate might further improve the outcome.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief